US Patent Issued to HUABO BIOPHARM (SHANGHAI) on June 24 for "Binder against programmed death-ligand application thereof" (Chinese Inventors)

ALEXANDRIA, Va., June 25 -- United States Patent no. 12,338,284, issued on June 24, was assigned to HUABO BIOPHARM (SHANGHAI) Co. LTD. (Shanghai).

"Binder against programmed death-ligand application thereof" was invented by Haijia Yu (Shanghai), Ling Yu (Shanghai), Mingqing Cai (Shanghai) and Xiangyang Zhu (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is an anti-PD-L1 monoclonal antibody. The antibody can be used to prepare a drug for preventing or treating a disease related to PD-L1."

The patent was filed on March 10, 2020, under Application No. 17/424,964.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&...